Friday, 15 Dec 2017

You are here

The RheumNow Week in Review – 13 January 2017

Dr. Jack Cush reviews highlights from this past week on RheumNow.com:

  1. ARTIS RA registry shows those initiating a TNFi within 5 yrs of onset double their odds of returning to work in 3 yrs https://t.co/WytSlSYRj1
  2. ARTIS & DANBIO registries: 8703 SpA (AS, PsA) patients treated with TNFI: they do NOT have an increase risk of cancer overall; nor the 6 most common types CA http://buff.ly/2icvD9O
  3. Hepatosplenic T cell lymphoma: review shows this to be a very rare event with TNFi; but is more common in IBD pts (younger), receiving thiopurines. http://buff.ly/2jn7Bqm
  4. Biosimilar Inflectra priced at only a 15% discount; CMS issues payment and claims processing information https://t.co/lCwn198PAN
  5. There is no interaction between low dose weekly MTX and NSAIDs, PCNs or PPIs. https://t.co/h4JeLoSbEg
  6. FDA reviewing a new drug application (NDA) for the new combo drug: allopurinol + lesinurad (Ironwood Pharm) to Rx hyperuricemia and uncontrolled gout https://t.co/e95R8TlXuv
  7. Meta-analysis of 1069 knee OA patients- intraarticular Platelet Rich Plasma (vs HA, NS) shows significantly better WOMAC pain/function scores. @12mo https://t.co/LBJt2SbZXO,
  8. Chronic PPI use associated with 74% more C difficile infections & 2.5-fold increased risk of recurrent C difficile with chronic PPI https://t.co/W1mLbPEPYP
  9. 13% of US African Americans have diabetes; but AA are seldom included in diabetes clinical trials. Whatsupwiththat? https://t.co/GYgXnAcyzb
  10. Total knee vs hemiarthroplasty show equal outcomes;more complications with bilateral total knee replacements (pt selection is critical to the success of hemiarthroplasty) https://t.co/D8OXH8VnTA
  11. 94 pts with MTX pancytopenia in elderly; 24% mortality; risk factors include age>65, sepsis + hypoalbuminemia https://t.co/7p99v9bt3g
  12. Multiple Comorbidity Risks with Giant Cell Arteritis
  13. Do Exercise ‘Weekend Warriors’ Lower Their Risk of Death? 
  14. The IL-6 Wars 
  15. DMARDs Under Study for Secondary Prevention of Cardiovascular Events

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 8 December 2017

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

Rheumatology Year in Review

During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.

Advances for Biologics

The ACR17 RheumNow Week in Review - 1 December 2017

Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.

ACR Clinical Guidelines Flawed by Low Evidence

JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations. 

RheumNow ACR 2017 Awards

The Annual Meeting of the American College of Rheumatology is a gargantuan educational and professional event that is on nearly everyone's radar each year. RheumNow had an expansive effort to cover this meeting and you can review the work of our faculty at ACR17.RheumNow.com.  But we have decided to take this one step further and today we are announcing our 2017 RheumNow ACR Awards.